Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (Review of NICE technology appraisals 162 and 175): A systematic review and economic evaluation

Health Technology Assessment

Volumn 19, Issue 47, 2015, Pages 1-8

  Greenhalgh, Janette ^a   Bagust, Adrian ^a   Boland, Angela ^a   Dwan, Kerry ^a   Beale, Sophie ^a   Hockenhull, Juliet ^a   Proudlove, Christine ^b   Dundar, Yenal ^a   Richardson, Marty ^a   Dickson, Rumona ^a   Mullard, Anna ^c   Marshall, Ernie ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Pharmacy Practice Unit   (United Kingdom)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PLACEBO; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

AGE DISTRIBUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG INDICATION; DRUG MECHANISM; ECONOMIC EVALUATION; ENZYME INHIBITION; GENE MUTATION; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; NON SMALL CELL LUNG CANCER; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; CARCINOMA, NON-SMALL-CELL LUNG; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; LUNG NEOPLASMS; PATHOLOGY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84936155815     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta19470     Document Type: Article

References (0)